Skip to main content
Top

06-04-2016 | Retinopathy | Review | Article

Laser Therapy in the Management of Diabetic Retinopathy

Journal: Current Ophthalmology Reports

Authors: Sejal Shah, Jorge Fortun

Publisher: Springer US

Abstract

Diabetic macular edema is the major cause of decreased vision in diabetic patients. This review explores laser treatment options beyond the established focal/grid laser photocoagulation protocol initially demonstrated in the Early Treatment of Diabetic Retinopathy Study. Subthreshold micropulse laser has been shown to be effective adjunctive therapy in conjunction with intravitreal anti-angiogenic injections in a subset of patients, specifically in those with a retinal thickness of less than 400 μm, without the risk of scotomas and potential vision loss, which can occur with conventional laser. Given the absence of scarring from this “invisible” laser, subthreshold micropulse laser may allow for earlier treatment prior to the onset of clinically significant macular edema, potentially preventing symptomatic vision loss and permanent photoreceptor damage.
Literature
1.
National Society to Prevent Blindness. Vision problems in the US: data analysis, definitions, data sources, detailed data tables, analyses, interpretation. New York: National Society to Prevent Blindness; 1980.
2.
Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology. 1984;91(12):1464–74.CrossRefPubMed
3.
Early Treatment of Diabetic Retinopathy Study. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. ETDRS report no. 2. Ophthalmology. 1987;94:761–74.CrossRef
4.
Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology. 1991;98:766–85.CrossRef
5.
Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118:609–14. doi:10.​1016/​j.​ophtha.​2010.​12.​033.CrossRefPubMedPubMedCentral
6.
Schmidt-Erfurth U, Lang GE, Holz FG, et al. Three-year outcomes of individualized Ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology. 2014;5:1045–53.CrossRef
7.
Schatz H, Madeira D, McDonald HR, Johnson RN. Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema. Arch Ophthalmol. 1991;109:1549–51.CrossRefPubMed
8.
Elman MJ, Ayala A, Bressler NM, et al. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5 year randomized clinical results. Ophthalmology. 2015;122(2):375–81.CrossRefPubMedPubMedCentral
9.
Luttrull J, Sramek C, Palanker D, et al. Long-term safety, high resolution imaging, and tissue temperature modeling of subvisible diode micropulse photocoagulation for retinovascular macular edema. Retina. 2012;32:375–86.CrossRefPubMed
10.
Luttrull JK, Musch DC, Mainster MA. Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular edema. Br J Ophthalmol. 2005;89:74–80.CrossRefPubMedPubMedCentral
11.
Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796–806.CrossRef
12.
Lewen RM. Subretinal neovascularization complicating laser photocoagulation of diabetic maculopathy. Ophthalmic Surg. 1988;19:734–7.PubMed
13.
Lewis H, Schachat AP, Haimann MH, et al. Choroidal neovascularization after laser photocoagulation for diabetic macular edema. Ophthalmology. 1990;97:503–10.CrossRefPubMed
14.
Guyer DR, D’Amico DJ, Smith CW. Subretinal fibrosis after laser photocoagulation for diabetic macular edema. Am J Ophthalmol. 1992;113:652–6.CrossRefPubMed
15.
Shah AM, Bressler NM, Jampol LM. Does laser still have a role in the management of retinal vascular and neovascular diseases? Am J Ophthalmol. 2011;152(3):332–9.CrossRefPubMed
16.
Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology. 1991;98:1594–602.CrossRefPubMed
17.
Writing Committee for the Diabetic Retinopathy Clinical Research. Network comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol. 2007;125(4):469–80.CrossRef
18.
Dorin G. Evolution of retinal laser therapy: minimum intensity photocoagulation (MIP). Can the laser heal the retina without harming it? In: Seminars in Ophthalmology. 2004. Vol. 19, No. 1–2, p. 62–8.
19.
Mainster MA. Decreasing retinal photocoagulation damage: principles and techniques. In: Seminars in Ophthalmology. 1999. p. 200–9.
20.
Akduman L, Olk RJ. Subthreshold (subvisible) modified grid diode laser photocoagulation in diffuse diabetic macular edema (DDME). Ophthalmic Surg Lasers. 1999;30:706–14.PubMed
21.
Roider J, Brinkmann R, Wirbelauer C, et al. Subthreshold (retinal pigment epithelium)photocoagulation in macular diseases: a pilot study. Br J Ophthalmol. 2000;84:40–7.CrossRefPubMedPubMedCentral
22.
Olk RJ, Akduman L. Minimal intensity diode laser (810 nanometer) photocoagulation (MIP) for diffuse diabetic macular edema (DDME). Sem Ophthalmol. 2001;16:25–30.CrossRef
23.
Friberg TR, Karatza EC. The treatment of macular disease using a micropulsed and continuous wave 810-nm diode laser. Ophthalmoogy. 1997;104:2030–8.CrossRef
24.
Moorman CM, Hamilton AM. Clinical applications of the MicroPulse diode laser. Eye. 1999;13:145–50.CrossRefPubMed
25.
Luttrull JK, Dorin G. Subthreshold diode micropulse laser photocoagulation (SDM) as invisible retinal phototherapy for diabetic macular edema: a review. Curr Diabetes Rev. 2012;8:274–84.CrossRefPubMedPubMedCentral
26.
Marshall J, Clover G, Rothery S. Some new findings of retinal irradiation by krypton and argon lasers. In: Birngruber R, Gabel V-P, editors. Laser treatment and photocoagulation of the eye. Doc Ophthalmol Proc Series 36. The Hague: Junk; 1984. p. 21–37.
27.
Yamamoto C, Ogata N, Yi X, et al. Immunolocalization of transforming growth factor â during wound repair after laser photocoagulation. Graefes Arch Clin Exp Ophthalmol. 1998;236:41–6.CrossRefPubMed
28.
Yoshimura N, Matsumoto M, Shimizu H, et al. Photocoagulated human retinal pigment epithelial cells produce an inhibitor of vascular endothelial cell proliferation. Invest Ophthalmol Vis Sci. 1995;36:1686–91.PubMed
29.
Framme C, Walter A, Prahs P, et al. Structural changes of the retina after conventional laser photocoagulation and selective retina treatment (SRT) in spectral domain OCT. Curr Eye Res. 2009;34:568–79.CrossRefPubMed
30.
Roider J, Michaud N, Flotte T, Birngruber R. Histology of retinal lesions after continuous irradiation and after selective microcoagulation of the retinal pigment epithelium. Ophthalmologe. 1993;90(3):274–8.PubMed
31.
Roider J, Liew SHM, Klatt C, et al. Selective retina therapy (SRT) for clinically significant diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2010;248(9):1263–72.CrossRefPubMed
32.
Laursen ML, Moeller F, Sander B, et al. Subthreshold micropulse diode laser treatment in diabetic macular oedema. Br J Ophthalmol. 2004;88:1173–9.CrossRefPubMedPubMedCentral
33.
•• Mansouri A, Sampat KM, Malik KJ, et al. Efficacy of subthreshold micropulse laser in the treatment of diabetic macular edema is influenced by pre-treatment central foveal thickness. Eye. 2014;28:1418–24. This article explains the importance of patient selection when deciding who may benefit most from subthreshold micropulse laser. Patient with mild to moderate edema benefit the most, while intravitreal anti-VEGF therapy may be reserved for those with increased central foveal thickness.
34.
Luttrull JK, Spink CA. Serial optical coherence tomography of subthreshold diode micropulse photocoagulation for diabetic macular edema. Opthalmic Surg Lasers Imaging. 2006;37:370–7.
35.
Vujosevic S, Bottega E, Casciano M, et al. Microperimetry and fundus autofluorescence in diabetic macular edema, subthreshold micropulse diode laser versus modified Early Treatment Diabetic Retinopathy Study laser photocoagulation. Retina. 2010;30:903–16.CrossRef
36.
Lavinksy D, Cardillo JA, Melo LA Jr, et al. Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photocoagulation for diabetic macular edema. Invest Ophthalmol Vis Sci. 2011;52(7):4314–23.CrossRef
37.
• Vujosevic S, Martini F, Longhin E, et al. Subthreshold micropulse yellow laser versus subthreshold micropulse infrared laser in center-involving diabetic macular edema: morphologic and functional safety. Retina. 2015;35:1594–603. The safety of Subthreshold Micropulse Yellow laser and Subthreshold Infrared Laser were established at certain parameters without any visible laser spots seen on any imaging modalities.
38.
•• Luttrull JK, Sinclair SH. Safety of transfoveal subthreshold diode micropulse laser for fovea-involving diabetic macular edema in eyes with good visual acuity. Retina. 2014;34:2010–20. The safety of Transfoveal Subthreshold Diode Micropulse laser was established. There was no evidence of any macular damage on any imaging devices. Patients in this study had good visual acuity (20/40 or better) allowing for safe alternative options in the treatment of diabetic macular edema.
39.
Figueira J, Khan J, Nunes S. Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular edema. Br J Ophthalmol. 2009;93:1341–4.CrossRefPubMed
40.
Brown JC, Solomon SD, Bressler SB. Detection of diabetic foveal edema. Arch Ophthalmol. 2004;122:330–5.CrossRefPubMed
41.
Channa R, Sophie R, Khwaja AA, et al. Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab. Eye. 2014;28:269–78.CrossRefPubMedPubMedCentral

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »